An interventional study of tourniquet binding of cervical in Amniotic Fluid Embolism and Pulmonary Hypertension, sponsored by First People's Hospital of Chenzhou. Not yet recruiting at 1 site in China. Open to female participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-12.
Sponsored by First People's Hospital of Chenzhou · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.
Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 43rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 35 other live ones, and was the 60th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Xiamen Cardiovascular Hospital, Xiamen University · Sites in China
Ages 18–80
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 20 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 21 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 100 across the 47 interventional studies, 750 across the 36 observational. Of the 38 that completed or were terminated, 14 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 85 have an industry lead sponsor. The 10 most frequent:
First People's Hospital of Chenzhou is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
First People's Hospital of Chenzhou has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypertension, Pulmonary with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT06023134Jingyi RenClinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure | 2027-09-01 |
| NCT06980584Beijing Chao Yang HospitalStudy on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Hypertension, Pulmonary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was conducted to investigate whether the use of tourniquet after delivery of the fetus could reduce the amount of amniotic fluid entering the bloodstream and thus reduce the incidence of intraoperative adverse events.
Amniotic fluid embolism (AFE) is a rare complication specially to obstetrics.When amniotic fluid enters the maternal circulation , a sudden onset of a series of pathophysiologic changes such as pulmonary hypertension, hypoxemia, circulatory failure, disseminated intravascular coagulation, and multiorgan failure may occur. Routinely, the typical AFE triad is uneasy to discover, and nonspecific adverse reactions such as irritability, chills, chest tightness and shortness of breath, transient drop in blood pressure, and nausea and vomiting are often seen during delivery of the fetus and placenta. All of the above symptoms may suggest that the amniotic fluid has entered into the bloodstream. In clinical anesthesia, investigators observed that women with placenta praevia and placenta implantation were less likely to suffer these nonspecific symptoms after delivery of the fetus compared with women with normal pregnancies.The investigators speculated it might be related to the fact that obstetricians used tourniquets to reduce intraoperative hemorrhage in the former, blocking venous return to the lower uterine segments to reduce the inflow of amniotic fluid into the uterus. Therefore, this study was conducted to investigate whether the use of tourniquet after delivery of the fetus could reduce the amount of amniotic fluid entering the bloodstream and thus reduce the incidence of intraoperative adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigators use tourniquets to bind the cervical for intervention groups to block venous return to the lower uterine segments to reduce the inflow of amniotic fluid into the uterus.
Procedure: tourniquet binding of cervical
The procedure will be performed by surgeons with rich experience in clinical work
sTn
sTn refers to meconium and mucin extracted from amniotic fluid. The presence of sTn in the patient's serum is a diagnostic method that can directly prove that mucin derived from amniotic fluid has entered the maternal circulation.
Time frame: before the fetus is delivered,after the fetus is delivered,before the puerpera is sent back to the ward
HR MAP
Measurement of HR by patient monitor and MAP by placing an arterial puncture catheterization.
Time frame: before the fetus is delivered,after the fetus is delivered,before the placenta is delivered,after the placenta is delivered,after releasing the tourniquet,before the puerpera is sent back to the ward
SPO2,PaO2,PaCO2
the respiratory parameters in arterial blood gas
Time frame: before the fetus is delivered,after the fetus is delivered,before the placenta is delivered,after the placenta is delivered,after releasing the tourniquet,before the puerpera is sent back to the ward
Thrombelastogram(TEG)
Thrombelastography (TEG) is an indicator of the dynamic changes of blood coagulation. It can evaluate thrombelastography and compensate for the failure of routine examinations to reflect the fibrinolytic system and platelet function.
Time frame: before the fetus is delivered,before the puerpera is sent back to the ward
Adverse events
Irritability, chills, chest tightness and shortness of breath, transient drop in blood pressure, and nausea and vomiting
Time frame: perioperatively
Hemorrhage
The using of tourniquets can reduce intraoperative hemorrhage. The postpartum hemorrhage reflects the coagulation function of patients.
Time frame: before the puerpera is sent back to the ward, 2 hours after the puerpera back to ward
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2024; primary completion for Jul 2024, 5 months later.
Of 135 non-industry interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's planned 5 months is below that.
Counting every sponsor, half of 150 studies reached it within 23 months; a quarter within 9 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First People's Hospital of Chenzhou